NCT02142192View on ClinicalTrials.gov

Natalizumab Subcutaneous Immunogenicity and Safety Study

PHASE2TerminatedINTERVENTIONAL

Enrollment

2

Participants

Timeline

Start Date

December 1, 2014

Primary Completion Date

June 4, 2015

Study Completion Date

June 4, 2015

Conditions

Relapsing Multiple Sclerosis

Interventions

DRUG

natalizumab

Administered as specified in the treatment arm

Trial Locations (2)

3000

Research Site, Leuven

4000

Research Site, Liège

Sponsors

Lead Sponsor

All Listed Sponsors

lead

Biogen

INDUSTRY